Objective Analysis.
Real-World Impact.

Verdant Research provides independent, objective analysis to inform the future of U.S. prescription drug policy. We combine rigorous modeling with deep policy expertise to support smarter policy and business decisions in pharmaceutical markets.

What We Do

Clarity Across Complex Drug Policy Decisions

Verdant provides economic and policy expertise across the core forces shaping U.S. prescription drug markets.

Policy Analysis & Development
Data Analytics & Modeling
Litigation & Expert Testimony

Recent Work

See All Work
October 2026

Pharmaceutical Innovation and the Inflation Reduction Act: 2026 Mid-Year Review

We follow 19 biopharma companies that have had or are likely to have a drug selected for Medicare negotiation as a result of the Inflation Reduction Act (IRA) of 2022. 

→
August 2026 Medicare Negotiation

The Economics of Orphan Blockbuster Drug Development

We studied whether blockbuster orphan drugs protected from Medicare Negotiation differ from non-orphan peers in their ability to recover clinical development costs.

→

Lead with Evidence

Partner with Verdant for rigorous, objective economic analysis.